Overview

Lessening Organ Dysfunction With VITamin C

Status:
Active, not recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

LOVIT is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at 28 days in septic intensive care unit patients. Patients with COVID-19 are considered eligible for this study.

Phase:

Phase 3

Details

Lead Sponsor:

Université de Sherbrooke

Collaborator:

Lotte & John Hecht Memorial Foundation

Treatments:

Ascorbic Acid
Vitamins